他可莫司血药浓度监测

 目的：为临床肾移植患者他可莫司(FK506)的合理用药提供参考。方法：采用微粒子酶免分析法对206例肾移植患者进行血药浓度监测, 并对其结果及疗效进行分析总结。结果：为206例肾移植患者监测了1732例次FK506血药浓度, 其中有效血药浓度范围内的有917例次, 占52.9%; 低于有效血药浓度的有649例次, 占37.5%; 高于有效血药浓度的有166例次, 占9.6%。结论：为用药安全有效, 应监测FK506血药浓度，实行个体化给药。

Monitoring whole blood concentration of FK506

OBJECTIVE To give some information for rationally administrating oral FK506 to renal transplant patients in clinic. METHODS The whole blood concentration of FK506 on 206 renal transplant patients was determined by microparticle eniyme immuno assay, the results and the therapeutic effect were studied. RESULTS Of 1732 cases in 206 renal transplant patients received FK506, the whole blood concentrations of 917 cases with effective level were accounted for 52.9%; and the whole blood concentrations of 649 cases were below effective level, accounting for 37.5%; while 84 cases whose whole blood concentrations were high effective level, accounting for 9.6%. CONCLUSIONS To be safe and effective for clinical use, it is important for renal transplant patients to monitor whole blood concentrations of FK506 with individualized drug adminstration.